ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Pharmacological inhibition of CDK7 and CDK9 suppresses gastrointestinal (colon) cancer progression through modulation of stemness, epithelial-mesenchymal transition, and chemoresistance.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastrointestinal (GI) cancers remain a leading cause of cancer-related mortality worldwide, with limited therapeutic options for advanced disease due to tumor heterogeneity, metastasis, cancer stemness, and acquired drug resistance. Cyclin-dependent kinases 7 and 9 (CDK7/9) are key regulators of transcription and cell-cycle progression, and their aberrant activation sustains oncogenic transcriptional programs. GNE-3511 is a dual CDK7/9 inhibitor with favorable pharmacokinetics, making it a promising therapeutic candidate for cancer treatment. The aim of the study is to investigate the anticancer efficacy and molecular mechanisms of GNE-3511 in gastrointestinal cancer models. Anticancer activity was evaluated in colorectal (HCT116), hepatocellular (HepG2), gastric (NCI-N87), and pancreatic (PanC1) cancer cells using cell viability, cell-cycle, apoptosis, migration, sphere formation, cancer stem cell, and doxorubicin accumulation assays. Expression of genes and proteins associated with apoptosis, epithelial-mesenchymal transition (EMT), stemness, multidrug resistance, and CDK7/9 signaling was analyzed by RT-qPCR and immunoblotting. Therapeutic efficacy was validated in an HCT116 xenograft model, with molecular analyses confirming the underlying anticancer mechanisms. GNE-3511 treatment reduced cell viability in all GI cancer cell lines, with the greatest potency in HepG2 followed by HCT116 cells. Further, GNE-3511 treatment induced G1 or G2/M cell-cycle arrest and promoted apoptosis by increasing BAX expression and suppressing BCL2, MCL1, and Survivin. GNE-3511 significantly reduced CD133⁺ and CD90⁺ cancer stem cell populations, inhibited migration, spheroid formation, and downregulated the stemness- and EMT-associated regulators Nanog, Snail, Twist, Vimentin, and Zeb1. Moreover, GNE-3511 enhanced intracellular accumulation of doxorubicin by repressing the multidrug resistance transporters ABCB1, ABCC9, and ABCG2. In HCT116 xenografts, GNE-3511 markedly suppressed tumor growth while reproducing the molecular effects observed in vitro. Furthermore, GNE-3511 did not cause treatment-related abnormalities, indicating favorable safety. Mechanistically, GNE-3511 inhibited CDK7/9 signaling, resulting in RB hypophosphorylation, suppression of POLR2A, and depletion of the oncogenic transcriptional regulators cMyc and MCL1. GNE-3511 exerts potent anticancer activity by disrupting CDK7/9-dependent transcriptional programs that regulate proliferation, apoptosis, stemness, EMT, and multidrug resistance. These findings identify GNE-3511 as a potential lead candidate for the treatment of colorectal cancers.
Indexed as
Identifiers
42624930What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.